Valera A, Pujol A, Gregori X, Riu E, Visa J, Bosch F
Department of Biochemistry and Molecular Biology, School of Veterinary Medicine, Autonomous University of Barcelona, Bellaterra, Spain.
FASEB J. 1995 Aug;9(11):1067-78. doi: 10.1096/fasebj.9.11.7649406.
The product of the c-myc proto-oncogene (c-Myc) is involved in the control of cell proliferation, differentiation, and apoptosis. It acts as a transcription factor that recognizes the CACGTG motif. This sequence has also been found in the glucose-responsive elements of genes involved in the control of liver glycolysis and lipogenesis. To determine whether c-Myc can regulate hepatic carbohydrate metabolism in vivo, transgenic mice that overexpress c-myc under control of the P-enolpyruvate carboxykinase (PEPCK) gene promoter have been generated. These mice showed a threefold increase in c-Myc protein in liver nuclei. Hepatocytes from transgenic mice were normal and did not acquire the fetal phenotype. However, transgenic mice showed higher levels (threefold) of L-type pyruvate kinase mRNA and enzyme activity than control mice. The increase in pyruvate kinase activity led to a three- to fivefold increase in liver lactate content and a fivefold induction of lactate production by hepatocytes in primary culture. The expression of the 6-phosphofructo-2-kinase gene was also increased in the liver of these transgenic mice. The induction of hepatic glycolysis was related with an increase in the expression (about fourfold) and activity (about threefold) of liver glucokinase, whereas no change was noted in hexokinase-I. This change in glucokinase activity led to an increase in both glucose 6-phosphate and glycogen contents in the liver of transgenic mice. The expression of the liver-specific glucose transporter GLUT2 was also increased in transgenic mice, whereas no change was noted in the mRNA concentration of GLUT1. Furthermore, the changes of liver glucose metabolism led to a marked reduction of blood glucose (25%) and insulin (40%) concentrations in starvation, whereas the fall in both was only 10% in fed mice. Thus, liver glucose metabolism could determine the blood glucose and insulin set points in the transgenic mice. All these results indicated that the increase in c-Myc protein was able to induce liver glucose utilization and accumulation, and suggested that c-Myc transcription factor is involved in the control in vivo of liver carbohydrate metabolism.
原癌基因c-myc的产物(c-Myc)参与细胞增殖、分化和凋亡的调控。它作为一种转录因子,可识别CACGTG基序。该序列也存在于参与肝脏糖酵解和脂肪生成调控的基因的葡萄糖反应元件中。为了确定c-Myc在体内是否能调节肝脏碳水化合物代谢,已培育出在磷酸烯醇式丙酮酸羧激酶(PEPCK)基因启动子控制下过表达c-myc的转基因小鼠。这些小鼠肝细胞核中的c-Myc蛋白增加了三倍。转基因小鼠的肝细胞正常,未出现胎儿表型。然而,转基因小鼠的L型丙酮酸激酶mRNA水平和酶活性比对照小鼠高(三倍)。丙酮酸激酶活性的增加导致肝脏乳酸含量增加三到五倍,原代培养肝细胞的乳酸生成诱导增加五倍。这些转基因小鼠肝脏中6-磷酸果糖-2-激酶基因的表达也增加。肝脏糖酵解的诱导与肝脏葡萄糖激酶表达(约四倍)和活性(约三倍)的增加有关,而己糖激酶-I没有变化。葡萄糖激酶活性的这种变化导致转基因小鼠肝脏中6-磷酸葡萄糖和糖原含量增加。转基因小鼠肝脏特异性葡萄糖转运蛋白GLUT2的表达也增加,而GLUT1的mRNA浓度没有变化。此外,肝脏葡萄糖代谢的变化导致饥饿时血糖(25%)和胰岛素(40%)浓度显著降低,而在喂食小鼠中两者仅下降10%。因此,肝脏葡萄糖代谢可以决定转基因小鼠的血糖和胰岛素设定点。所有这些结果表明,c-Myc蛋白的增加能够诱导肝脏葡萄糖的利用和积累,并提示c-Myc转录因子参与体内肝脏碳水化合物代谢的调控。